ECSP014078A - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
ECSP014078A
ECSP014078A EC2001004078A ECSP014078A ECSP014078A EC SP014078 A ECSP014078 A EC SP014078A EC 2001004078 A EC2001004078 A EC 2001004078A EC SP014078 A ECSP014078 A EC SP014078A EC SP014078 A ECSP014078 A EC SP014078A
Authority
EC
Ecuador
Prior art keywords
sulfonamide derivatives
hypofusion
psychiatric
graph
useful
Prior art date
Application number
EC2001004078A
Other languages
English (en)
Inventor
George William Cuff
Thomas John Bleisch
Paul Leslie Ornstein
Dennis Michael Zimmerman
Macklin Brian Arnold
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP014078A publication Critical patent/ECSP014078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I (gráfico), o una sal farmacéuticamente aceptable del mismo, que es útil para el tratamiento de defencias asociadas con la hipofusión como trastornos psiquiátricos y neurológicos.
EC2001004078A 2000-05-19 2001-05-18 Derivados de sulfonamida ECSP014078A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20600300P 2000-05-19 2000-05-19

Publications (1)

Publication Number Publication Date
ECSP014078A true ECSP014078A (es) 2002-02-25

Family

ID=22764580

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004078A ECSP014078A (es) 2000-05-19 2001-05-18 Derivados de sulfonamida

Country Status (24)

Country Link
US (1) US20030225163A1 (es)
EP (1) EP1311474A1 (es)
JP (1) JP2003534316A (es)
KR (1) KR20030007644A (es)
CN (1) CN1429205A (es)
AR (1) AR035915A1 (es)
AU (1) AU2001259053A1 (es)
BR (1) BR0110874A (es)
CA (1) CA2409830A1 (es)
CZ (1) CZ20023797A3 (es)
DZ (1) DZ3343A1 (es)
EA (1) EA200201234A1 (es)
EC (1) ECSP014078A (es)
HR (1) HRP20020918A2 (es)
HU (1) HUP0302255A3 (es)
IL (1) IL152156A0 (es)
MX (1) MXPA02010020A (es)
NO (1) NO20025459L (es)
PE (1) PE20020052A1 (es)
PL (1) PL358180A1 (es)
SK (1) SK16312002A3 (es)
SV (1) SV2002000459A (es)
WO (1) WO2001090057A1 (es)
ZA (1) ZA200208749B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6984756B2 (en) 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
ES2225558T3 (es) 2000-06-13 2005-03-16 Eli Lilly And Company Derivados de sulfonamida.
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
US8097652B2 (en) 2006-12-11 2012-01-17 Eli Lilly And Company AMPA receptor potentiators
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
US20190112300A1 (en) 2016-03-29 2019-04-18 Arnold Stan Lippa Compositions And Methods For Treating Attention Deficit Disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525099B1 (en) * 1998-07-31 2003-02-25 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
AU2001259053A1 (en) 2001-12-03
DZ3343A1 (fr) 2001-11-29
IL152156A0 (en) 2003-05-29
CA2409830A1 (en) 2001-11-29
EA200201234A1 (ru) 2003-04-24
AR035915A1 (es) 2004-07-28
MXPA02010020A (es) 2003-02-12
KR20030007644A (ko) 2003-01-23
EP1311474A1 (en) 2003-05-21
CN1429205A (zh) 2003-07-09
HUP0302255A3 (en) 2005-11-28
SV2002000459A (es) 2002-07-03
US20030225163A1 (en) 2003-12-04
NO20025459D0 (no) 2002-11-14
WO2001090057A1 (en) 2001-11-29
CZ20023797A3 (cs) 2003-04-16
HRP20020918A2 (en) 2004-02-29
NO20025459L (no) 2002-11-14
PL358180A1 (en) 2004-08-09
JP2003534316A (ja) 2003-11-18
PE20020052A1 (es) 2002-02-02
BR0110874A (pt) 2003-02-11
SK16312002A3 (sk) 2003-05-02
HUP0302255A2 (hu) 2003-11-28
ZA200208749B (en) 2004-01-30

Similar Documents

Publication Publication Date Title
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
PA8591701A1 (es) Derivados de pirrolopirimidina
BR0311494A (pt) Novos indóis substituìdos
BR0312729A (pt) Novos derivados de indol-3-enxofre
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
DOP2006000170A (es) Nuevos derivados de espirocromanona
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ES2189357T3 (es) Compustos isocromano y procedimiento para su produccion.
DE60104697D1 (de) Sulfonamid-derivate
ECSP014079A (es) Derivados de sulfonamida
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE0101082D0 (sv) Novel use
BRPI0317188A8 (pt) novo derivado de 2,4-diamino-1,3,5-triazina
SV2002000459A (es) Derivados de sulfonamidas ref. x-13840
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES